Placental growth hormone in Down's syndrome screening

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 16, Issue 4, 2004, Pages 241-243

  Baviera, G ^a,b   Carbone, C ^a   Corrado, F ^a   Mastrantonio, P ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Down's syndrome; Placental growth hormone; Triple test

Indexed keywords

BIOLOGICAL MARKER; GROWTH HORMONE; HUMAN PLACENTAL GROWTH HORMONE; UNCLASSIFIED DRUG;

ANEUPLOIDY; ARTICLE; BLOOD LEVEL; CALCULATION; CONTROLLED STUDY; DOWN SYNDROME; FETUS; HUMAN; MATERNAL BLOOD; PREGNANCY; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY ANALYSIS; TRIPLE TEST;

ADULT; CASE-CONTROL STUDIES; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; GROWTH HORMONE; HUMANS; PLACENTAL HORMONES; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 10644280010     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/14767050400003736     Document Type: Article

References (3)

1. Moghadam S, Engel W, Bougoussa M, et al. Maternal serum placental hormone and insulinlike growth factor binding proteins 1 and 3 in pregnancies affected by fetal aneuploidy and other abnormalities: implications for prenatal diagnosis of trisomy 21. Fetal Diagn Ther 1998;13:291-7
2. Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stat Med 1992;11:257-68
3. Cuckle HS. Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 1995;15:1057-65